As part of a translational clinical trial for canine osteosarcoma (OS), I characterized the interactions of carboplatin, a common chemotherapy used to treat OS patients, with an innate immune pathway agonist used in the clinical trial. As part of my research, I optimized protocols to study these interactions in canine and murine cell lines, established a murine model of OS, and began optimizing a combination therapeutic approach of carboplatin with our experimental immune agonist.